
Benzinga Pro data, Fate Therapeutics (NASDAQ:FATE) reported Q4 sales of $17.07 million. Earnings fell to a loss of $68.62 million, resulting in a 58.45% decrease from last quarter. In Q3, Fate Therapeutics brought in $14.22 million in sales but lost $43.31 million in earnings.